Marshall Wace, LLP Ultragenyx Pharmaceutical Inc. Transaction History

Marshall Wace, LLP

  • $90.8 Billion
  • Q3 2025

A detailed history of Marshall Wace, LLP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 146,094 shares of RARE stock, worth $4.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
146,094
Previous 65,871 121.79%
Holding current value
$4.83 Million
Previous $2.4 Million 83.47%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
BUY
$26.31 - $41.44 $2.11 Million - $3.32 Million
80,223 Added 121.79%
146,094 $4.39 Million
Q2 2025

Aug 13, 2025
SELL
$31.06 - $39.3 $8.33 Million - $10.5 Million
-268,207 Reduced 80.28%
65,871 $2.4 Million
Q1 2025

May 15, 2025
SELL
$36.21 - $45.78 $26 Million - $32.8 Million
-717,495 Reduced 68.23%
334,078 $12.1 Million
Q4 2024

Feb 13, 2025
BUY
$42.07 - $57.72 $9.66 Million - $13.3 Million
229,561 Added 27.93%
1,051,573 $44.2 Million
Q3 2024

Nov 14, 2024
SELL
$40.21 - $59.36 $12.5 Million - $18.5 Million
-311,088 Reduced 27.45%
822,012 $45.7 Million
Q2 2024

Aug 14, 2024
BUY
$37.42 - $51.61 $6.14 Million - $8.47 Million
164,110 Added 16.94%
1,133,100 $46.6 Million
Q1 2024

May 15, 2024
SELL
$43.02 - $53.69 $22.4 Million - $27.9 Million
-520,496 Reduced 34.94%
968,990 $45.2 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $17.4 Million - $27 Million
548,723 Added 58.33%
1,489,486 $71.2 Million
Q3 2023

Nov 14, 2023
BUY
$34.92 - $46.66 $493,279 - $659,119
14,126 Added 1.52%
940,763 $33.5 Million
Q2 2023

Aug 14, 2023
BUY
$37.35 - $52.15 $788,533 - $1.1 Million
21,112 Added 2.33%
926,637 $42.7 Million
Q1 2023

May 15, 2023
BUY
$36.99 - $48.71 $21.1 Million - $27.8 Million
570,100 Added 169.96%
905,525 $36.3 Million
Q4 2022

Feb 14, 2023
BUY
$33.72 - $46.33 $8.59 Million - $11.8 Million
254,711 Added 315.57%
335,425 $15.5 Million
Q3 2022

Nov 14, 2022
SELL
$39.96 - $66.14 $10.8 Million - $17.9 Million
-270,936 Reduced 77.05%
80,714 $3.34 Million
Q2 2022

Aug 15, 2022
SELL
$45.8 - $85.4 $1.55 Million - $2.89 Million
-33,803 Reduced 8.77%
351,650 $21 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $9.41 Million - $12.8 Million
151,223 Added 64.56%
385,453 $28 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $15.1 Million - $17.9 Million
204,288 Added 682.28%
234,230 $19.7 Million
Q3 2021

Nov 15, 2021
SELL
$77.92 - $102.4 $435,339 - $572,108
-5,587 Reduced 15.73%
29,942 $2.7 Million
Q2 2021

Aug 13, 2021
BUY
$92.19 - $115.71 $3.28 Million - $4.11 Million
35,529 New
35,529 $3.39 Million
Q1 2021

May 17, 2021
SELL
$106.9 - $167.73 $2.78 Million - $4.36 Million
-26,014 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$84.4 - $177.39 $2.2 Million - $4.61 Million
26,014 New
26,014 $3.6 Million

Others Institutions Holding RARE

# of Institutions
347
Shares Held
88.6M
Call Options Held
2.19M
Put Options Held
1.04M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.32B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email